13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

7 trials found

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-001549-42-GB (EUCTR)	27/03/2020	03/02/2020	Stem cell transplantation versus disease modifying therapy (alemtuzumab or ocrelizumab) for patients ...	A multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic ste ...	Highly active relapsing remitting multiple sclerosis MedDRA version: 20.1;Level: PT;Classification c ...	Product Name: Cyclophosphamide INN or Proposed INN: Cyclophosphamide monohydrate INN or Proposed INN: C ...	Sheffield Teaching Hospitals	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	198	Phase 3	United Kingdom
2	NCT03829566 (ClinicalTrials.gov)	November 2019	1/2/2019	Autologous Transplant To End NMO Spectrum Disorder	Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica;Devic's Disease;NMO Spectrum Disorder	Drug: Rituximab;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;B ...	Northwestern University	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 2/Phase 3	United States
3	NCT03342638 (ClinicalTrials.gov)	November 8, 2017	9/11/2017	Maximizing Outcome of Multiple Sclerosis Transplantation	Maximizing Outcome of Multiple Sclerosis Transplantation: MOST Trial	Multiple Sclerosis, Relapsing-Remitting	Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg; ...	Northwestern University	NULL	Terminated	18 Years	58 Years	All	66	Phase 3	United States
4	EUCTR2007-000586-38-IT (EUCTR)	21/12/2007	10/01/2008	HIGH-DOSE IMMUNOSUPPRESSION WITH THIOTEPA AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM CELL TRAN ...	HIGH-DOSE IMMUNOSUPPRESSION WITH THIOTEPA AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM CELL TRAN ...	PATIENTS AFFECTED BY MULTIPLE SCLEROSIS MedDRA version: 6.1;Level: HLT;Classification code 10052785	Trade Name: THIOPLEX INN or Proposed INN: Thiotepa Trade Name: ENDOXAN BAXTER INN or Proposed INN: Cyclo ...	OSPEDALE S. RAFFAELE	NULL	Not Recruiting			Female: yes Male: yes	30	Phase 2	Italy
5	NCT00288626 (ClinicalTrials.gov)	July 2006	7/2/2006	High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study	A Phase II Study of High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, Mel ...	Relapsing-Remitting Multiple Sclerosis	Drug: Granulocyte-colony stimulating factor (G-CSF) and prednisone;Drug: Carmustine , etoposide, cyta ...	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN)	Completed	18 Years	60 Years	All	25	Phase 2	United States
6	NCT00017628 (ClinicalTrials.gov)	April 2001	6/6/2001	Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Au ...		Multiple Sclerosis	Drug: cyclophosphamide;Drug: filgrastim;Drug: methylprednisolone;Procedure: Autologous Stem Cell Tra ...	Northwestern Memorial Hospital	NULL	Completed	N/A	59 Years	Both	20	Phase 1	United States
7	NCT00014755 (ClinicalTrials.gov)	December 1997	10/4/2001	Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed ...		Multiple Sclerosis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: filgrastim;Drug: prednisone;Procedure: pe ...	Fred Hutchinson Cancer Research Center	NULL	Completed	18 Years	60 Years	Both	35	Phase 1	United States

First Previous1Next Last